scholarly journals Biomarkers in the setting of benign prostatic hyperplasia-induced lower urinary tract symptoms: what an interventional radiologist needs to know

2020 ◽  
Vol 93 (1114) ◽  
pp. 20200484
Author(s):  
Shamar Young ◽  
Alessandro Gasparetto ◽  
Hamed Jalaeian ◽  
Jafar Golzarian
Keyword(s):  
Prostate Cancer ◽  
Urinary Tract ◽  
Benign Prostatic Hyperplasia ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Specific Antigen ◽  
Prostate Cancer Risk ◽  
Prostatic Hyperplasia ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

With increasing evidence to support prostate artery embolization (PAE) in the treatment of benign prostatic hyperplasia (BPH)-induced lower urinary tract symptoms (LUTS), Interventional Radiologists have begun to play an important role in the management of these patients. One area of knowledge needed when developing a PAE practice is knowledge of prostate-specific antigen (PSA) and other biomarkers utilized to detect prostate cancer in this population and what role they should play in the work up and follow-up of patients presenting with presumed BPH-induced LUTS. Furthermore, understanding how to evaluate presumed BPH-induced LUTS and stratify the risk of prostate cancer is an important skill to develop. The goal of this review is to provide Interventional Radiologists who have begun or aim to begin a PAE practice with the information they need to know regarding PSA levels and prostate cancer risk stratification for this patient population.

1328: A Proteomic Urine Protein Study in Men with Benign Prostatic Hyperplasia or Prostate Cancer and Lower Urinary Tract Symptoms

2004 ◽  
Vol 171 (4S) ◽  
pp. 350-350
Author(s):  
Robert A. Henningsen ◽  
Stewart W. McCallum ◽  
Wanda Kwan ◽  
Brenda L. Schwartz ◽  
Kenneth M. Straub ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Urinary Tract ◽  
Benign Prostatic Hyperplasia ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Prostatic Hyperplasia ◽  
Urine Protein ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

scholarly journals The Effect of Seoritae Extract in Men with Mild to Moderate Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Woong Jin Bae ◽  
Hyo Jung Park ◽  
Hye Cheong Koo ◽  
Do Ram Kim ◽  
U-Syn Ha ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Benign Prostatic Hyperplasia ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Specific Antigen ◽  
Prostatic Hyperplasia ◽  
Outcome Variable ◽  
International Prostatic Symptom Score ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

We evaluated the effects of Seoritae extract (SE) on mild to moderate lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). Seventy-six subjects with mild to moderate LUTS suggestive of BPH were prospectively recruited from the urology outpatient clinic and assigned to either SE (4200 mg or 6 tablets 3 times a day) or matching placebo. The primary outcome variable, the International Prostatic Symptom Score (IPSS), was evaluated at baseline and at 4 and 12 weeks. Postvoid residual volume (PVR), maximum urine flow rate (Qmax), and prostate-specific antigen (PSA) levels were evaluated. IPSSs decreased significantly from baseline to 12 weeks within the SE group. Significant improvements in IPSS voiding scores at 4 and 12 weeks were also observed in the SE group compared to the placebo group. IPSS storage and quality of life scores were also significantly decreased at 12 weeks in the SE group. There was no change inQmaxor PVR in both groups after 12 weeks. Administration of SE for 12 weeks led to significant improvements in LUTS, and it can be concerned as a reasonable and safe alternative for men with mild to moderate LUTS.

Sign in / Sign up

Export Citation Format

Share Document